Novo Nordisk bolts on a ‘holy grail’ oral delivery platform in $1.8B buyout
A little over a year after Novo Nordisk shook up the big diabetes market with the approval of oral semaglutide, the pharma major is grabbing the tech used to convert the drug from a biologic into a ‘holy grail’ oral treatment in a $1.8 billion buyout.
Novo says it is paying $1.35 billion in cash for all shares of Emisphere with another $450 million being shelled out to buy the royalty stream due to MHR Fund Management — Emisphere’s biggest shareholder.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.